Literature DB >> 16633364

Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.

Yongfeng Shang1.   

Abstract

Endometrial cancer is the most common gynaecological cancer, and is associated with endometrial hyperplasia, unopposed oestrogen exposure and adjuvant therapy for breast cancer using selective oestrogen-receptor modulators (SERMs), particularly tamoxifen. Oestrogen and SERMs are thought to be involved in endometrial carcinogenesis through their effects on transcriptional regulation. Ultimately, oestrogen and SERMs affect the transduction of cellular signalling pathways that govern cell growth and proliferation, through downstream effectors such as PAX2 (paired box 2).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633364     DOI: 10.1038/nrc1879

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  89 in total

1.  CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.

Authors:  Qian Zhang; Rosemarie Schmandt; Joseph Celestino; Adrienne McCampbell; Melinda S Yates; Diana L Urbauer; Russell R Broaddus; David S Loose; Gregory L Shipley; Karen H Lu
Journal:  Gynecol Oncol       Date:  2014-04       Impact factor: 5.482

Review 2.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

3.  Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2.

Authors:  Yin-Yan He; Gui-Qiang Du; Bin Cai; Qin Yan; Long Zhou; Xiao-Yue Chen; Wen Lu; Yi-Xia Yang; Xiao-Ping Wan
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-24       Impact factor: 4.553

Review 4.  Bioactivation of Selective Estrogen Receptor Modulators (SERMs).

Authors:  Tamara S Dowers; Zhi-Hui Qin; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2006-09       Impact factor: 3.739

Review 5.  Divide or unite--a novel molecular switch in endometrial carcinoma.

Authors:  Martin Götte
Journal:  J Mol Med (Berl)       Date:  2006-10-27       Impact factor: 4.599

Review 6.  Endometriosis and nuclear receptors.

Authors:  Bahar D Yilmaz; Serdar E Bulun
Journal:  Hum Reprod Update       Date:  2019-07-01       Impact factor: 15.610

7.  Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.

Authors:  Bin Shi; Jing Liang; Xiaohan Yang; Yan Wang; Youna Zhao; Huijian Wu; Luyang Sun; Ying Zhang; Yupeng Chen; Ruifang Li; Yu Zhang; Mei Hong; Yongfeng Shang
Journal:  Mol Cell Biol       Date:  2007-05-14       Impact factor: 4.272

8.  Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling.

Authors:  Shanhu Li; Hongtao Wang; Liu Hong; Wei Liu; Fang Huang; Jian Wang; Peng Wang; Xiaoqing Zhang; Jianguang Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

9.  SIP, a novel ankyrin repeat containing protein, sequesters steroid receptor coactivators in the cytoplasm.

Authors:  Ying Zhang; Hua Zhang; Jing Liang; Wenhua Yu; Yongfeng Shang
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

10.  Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.

Authors:  Tetsuya Kokabu; Taisuke Mori; Hiroshi Matsushima; Kaori Yoriki; Hisashi Kataoka; Yosuke Tarumi; Jo Kitawaki
Journal:  Cell Oncol (Dordr)       Date:  2019-01-31       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.